Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 2/20 | 0.34 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL302379 | 0.89 | CA12 (0.35) | MEN1HTTKMT2AATRATRIP | |
| SCHEMBL424390 | 0.87 | LRRK2 (0.33) | MEN1TSHRHTTKMT2AFGFR1 | |
| SCHEMBL302800 | 0.87 | LRRK2 (0.33) | MEN1TSHRHTTKMT2AFGFR1 | |
| SCHEMBL302107 | 0.84 | ATR (0.39) | MCHR1ATRATRIPBRAFPIK3CA | |
| SCHEMBL303780 | 0.81 | BRAF (0.37) | MCHR1MEN1HTTKMT2AATR | |
| SCHEMBL302482 | 0.79 | PIK3CA (0.37) | MCHR1MEN1HTTKMT2AATR | |
| SCHEMBL303009 | 0.79 | MAPT (0.39) | MCHR1MEN1TSHRHTTKMT2A | |
| SCHEMBL302287 | 0.79 | ALDH1A1 (0.40) | MEN1TSHRKMT2AATRATRIP | |
| SCHEMBL303636 | 0.79 | MCHR1 (0.36) | MCHR1MEN1HTTKMT2AATR | |
| SCHEMBL301870 | 0.78 | BRAF (0.34) | MCHR1HTTATRATRIPBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4851337-B2 | — | — | 2012-01-11 | — | — | JP | claimed |
| US-7935698-B2 | Heteroaryl-hydrazone compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-05-03 | — | — | US | claimed |
| EP-1689403-A4 | HETEROARYL-HYDRAZONE COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2007-09-05 | — | — | EP | claimed |
| JP-2007510748-A | — | — | 2007-04-26 | — | — | JP | claimed |
| EP-1689403-A2 | HETEROARYL-HYDRAZONE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-16 | — | — | EP | claimed |
| US-20050282809-A1 | Heteroaryl-hydrazone compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | claimed |
| WO-2005046604-A2 | HETEROARYL-HYDRAZONE COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-7935698-B2 | Heteroaryl-hydrazone compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1689403-A4 | HETEROARYL-HYDRAZONE COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1689403-A2 | HETEROARYL-HYDRAZONE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050282809-A1 | Heteroaryl-hydrazone compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | disclosed |
| WO-2005046604-A2 | HETEROARYL-HYDRAZONE COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | MCHR1 2377/4885MEN1 4796/4885TSHR 4463/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | MCHR1 1832/4885MEN1 3751/4885TSHR 965/4885 |
| US-20050282809-A1 | Heteroaryl-hydrazone compounds | MMP12, IL1RN, CASP12 | MCHR1 723/4885MEN1 3324/4885TSHR 1617/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | MCHR1 1707/4885MEN1 293/4885TSHR 3663/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | MCHR1 1832/4885MEN1 3751/4885TSHR 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.